Timing of respiratory syncytial virus and influenza epidemic activity in five regions of Argentina, 2007‐2016

Baumeister, Elsa; Duque, Jazmin; Varela, Teresa; Palekar, Rakhee; Couto, Paula; Savy, Vilma L.; Giovacchini, Carlos; Rha, Brian; Arriola, Carmen Sofia; Gerber, Susan I.; Azziz‐Baumgartner, Eduardo

doi:10.1111/irv.12596

Cited by 13 publications

(14 citation statements)

References 26 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The weeks when RSV detections exceeded 1.2% of total RSVpositive specimens per season with one gap week allowed. 11 3. The weeks with ≥60% of each year's average weekly number of laboratory detections of RSV-positive specimen.…”

Section: Discussionmentioning

confidence: 99%

“…Different methods are in use. [9][10][11]18,19 In Slovenia, laboratory-based RSV surveillance was established in the year 2006. The start and the end of the RSV epidemic season were set on a 10% threshold-the weeks when more than 10% of samples tested positive composed the RSV epidemic season.…”

Section: Recommendations On the Timing And Duration Of Palivizumabmentioning

confidence: 99%

“…In regions with a temperate climate, RSV starts circulating in the autumn, peaks in winter and ends in spring 9‐12 . The onset and offset of RSV season are variable from year to year 13 .…”

Section: Introductionmentioning

confidence: 99%

“…8 In regions with a temperate climate, RSV starts circulating in the autumn, peaks in winter and ends in spring. [9][10][11][12] The onset and offset of RSV season are variable from year to year. 13 The variability may depend on temperature, humidity, precipitation and other environmental and social drivers of seasonality.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Determining the seasonality of respiratory syncytial virus in Slovenia

Grilc

Trilar

Lajovic³

et al. 2020

Influenza Resp Viruses

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a common cause of childhood acute respiratory infections and a major cause of hospital admissions in young children. 1 The public health importance of RSV is due, at least in low-income settings, to its high morbidity and mortality in young children. 2 The disease burden among the elderly population and people with chronic diseases like COPD is substantial as well and may be similar to that of seasonal influenza A virus infection in some seasons.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Recommendations On the Timing And Duration Of Palivizumabmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Determining the seasonality of respiratory syncytial virus in Slovenia

Grilc

Trilar

Lajovic³

et al. 2020

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…En el análisis de la ST y en el modelo GAM realizado, el componente estacional fue bien marcado, con un claro incremento de la mortalidad entre junio y setiembre, con pico en julio, similar al comportamiento observado en otros estudios (26-29).…”

Section: Discussionunclassified

Mortalidad atribuible a gripe en los períodos prevacunación y posvacunación en Argentina: estudio ecológico (2002-2016)

Sarrouf

Souza-Santos

Cruz

2019

Rev Panam Salud Publica

View full text Add to dashboard Cite

RESUMEN Objetivos Comparar las tasas de mortalidad por infección respiratoria aguda grave atribuible a gripe (IRAG) entre los períodos antes de la vacunación (AV) y después de la vacunación (DV), conocer la evolución histórica y estacionalidad de serie histórica entre 2002-2016 y estimar el riesgo de morir de niños entre 6 y 23 meses mediante el empleo de un modelo estadístico. Métodos Estudio de serie histórica con datos oficiales de mortalidad del informe estadístico de defunción. Se consideraron como IRAG los códigos de CIE-10 entre J09-18.9 y J22X. Se calcularon tasas brutas (TB) y ajustadas por edad (TAE) y se compararon los períodos AV (2002-2009) y DV (2010-2016) con prueba de χ 2. El mejor modelo estadístico fue el que comparó las defunciones por IRAG en niños durante el 2002 con otros años. Se analizaron los datos con programa R, nivel de significancia P <0,05. Resultados El 4,6% (301 747) de las defunciones fueron por IRAG, con una edad mediana de 82 años, el porcentaje de fallecidos menores de dos años disminuyó en el período DV (2,34% a 0,99%, P < 0,05). Se presentó una marcada estacionalidad en invierno. Las TAE en gerontes pasaron de 259,8 AV a 328,6 por 100 000 personas DV (P < 0,05). En los niños, la TB disminuyó de manera significativa, estimando que el riesgo de morir por IRAG, comparado con el año 2 002, fue significativamente menor durante 3 años DV. Conclusiones La disminución de la mortalidad por gripe en Argentina fue más evidente en niños, con un descenso estimado de 3,5 niños fallecidos por IRAG por mes.

show abstract

Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine During Pregnancy for Prevention of Respiratory Syncytial Virus Among Infants in Argentina

Rey-Ares,

Averin,

Zuccarino

et al. 2024

Infect Dis Ther

View full text Add to dashboard Cite

Introduction Lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV) is common among young children in Argentina. Use of the currently available prophylactic agent is limited to children aged ≤ 2 years with selected high-risk conditions, and thus the majority of infants remain unprotected. We estimated the value-based price (VBP) of a novel RSVpreF vaccine for use among pregnant people for prevention of RSV-LRTI among infants during the first year of life. Methods Clinical outcomes and economic costs of RSV-LRTI during infancy and expected impact of RSVpreF vaccination during pregnancy were projected using a population-based Markov-type cohort model. Model results—estimated on the basis of gestational age at birth, disease/fatality rates, and mother’s vaccination status—include total numbers of RSV-LRTI cases, RSV-LRTI-related deaths, and associated costs. Base case analyses (RSVpreF vs. no vaccine) were conducted from the healthcare system perspective. Probabilistic sensitivity analyses (PSA; 1000 replications) were also conducted. Willingness-to-pay (WTP) was $10,636 per quality-adjusted life-year (QALY; i.e., 1 × 2021 gross domestic product [GDP] per capita) in base case analyses and PSA. Costs are reported in USD, estimated on the basis of the June 22, 2023 exchange rate. Results Use of RSVpreF among 342,110 pregnant persons provided protection to 330,079 infants at birth. In total, RSVpreF prevented 3915 RSV hospitalizations, 6399 RSV cases requiring emergency department care, 6182 RSV cases requiring a physician office visit, and 67 disease-related deaths. Direct costs were projected to be reduced by $5.0 million. With 2061 QALYs gained and vaccine administration cost of $1.4 million, the VBP of RSVpreF was estimated to be $74.46 per dose. In PSA, mean VBP was $75.02 (95% confidence interval 54.24–97.30). Conclusions RSVpreF among pregnant persons would significantly reduce the clinical and economic burden of RSV-LRTI among infants in Argentina and would be considered a cost-effective intervention up to a price of approximately $75. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-024-01055-5.

show abstract

Timing of respiratory syncytial virus and influenza epidemic activity in five regions of Argentina, 2007‐2016

Abstract: In Argentina, RSV and influenza activity overlapped during the winter months. RSV season tended to begin prior to the influenza season, and showed more variation in start week by region. Influenza seasons tended to vary more in duration than RSV seasons.

Cited by 13 publications

References 26 publications

Determining the seasonality of respiratory syncytial virus in Slovenia

Determining the seasonality of respiratory syncytial virus in Slovenia

Mortalidad atribuible a gripe en los períodos prevacunación y posvacunación en Argentina: estudio ecológico (2002-2016)

Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine During Pregnancy for Prevention of Respiratory Syncytial Virus Among Infants in Argentina

Contact Info

Product

Resources

About